A Precision Medicine Initiative for Alzheimer’s disease: the road ahead to biomarker-guided integrative disease modeling

References

• Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860–921
   PubMed Web of Science ®Google Scholar
• Collins FS, Varmus HA. new initiative on precision medicine. N Engl J Med 2015;372:793–5
   PubMed Web of Science ®Google Scholar
• Lista S, Khachaturian ZS, Rujescu D, Garaci F, Dubois B, Hampel H. Application of systems theory in longitudinal studies on the origin and progression of Alzheimer’s disease. Methods Mol Biol 2016;1303:49–67
   PubMedGoogle Scholar
• Hampel H, Lista S, Khachaturian ZS. Development of biomarkers to chart all Alzheimer’s disease stages: the royal road to cutting the therapeutic Gordian Knot. Alzheimers Dement 2012;8:312–36
   PubMed Web of Science ®Google Scholar
• Alzheimer A. Über einen eigenartigen schweren. Erkrankungsprozeß der Hirnrinde. Neurologisches Centralblatt 1906;23:1129–36
   Google Scholar
• Kang J, Lemaire HG, Unterbeck A, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325:733–6
   PubMed Web of Science ®Google Scholar
• Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523–7
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173–7
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992;256:184–5
   PubMed Web of Science ®Google Scholar
• Van der Flier WM. Clinical heterogeneity in familial Alzheimer’s disease. Lancet Neurol 2016;15:1296–8
   PubMed Web of Science ®Google Scholar
• Portelius E, Andreasson U, Ringman JM, et al. Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer’s disease. Mol Neurodegener 2010;5:2
   PubMed Web of Science ®Google Scholar
• Younesi E, Hofmann-Apitius M. From integrative disease modeling to predictive, preventive, personalized and participatory (P4) medicine. Epma J 2013;4:23
   PubMedGoogle Scholar
• Hampel H, O’Bryant SE, Castrillo JI, et al. Precision medicine: the golden gate for detection, treatment and prevention of Alzheimer’s disease. J Prev Alz Dis 2016;3:243–59
   Google Scholar
• Khachaturian ZS, Khachaturian AS. The paradox of research on dementia: Alzheimer’s disease. J Prev Alz Dis 2016;3:189–91
   Google Scholar
• National Research Council (US) Committee on a Framework for Developing a New Taxonomy of Disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease. Washington (DC): National Academies Press, 2011
   Google Scholar
• Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 2014;13:614–29
   PubMed Web of Science ®Google Scholar
• Hampel H, Lista S, Teipel SJ, et al. Perspective on future role of biological markers in clinical therapy trials of Alzheimer’s disease: a long-range point of view beyond 2020 . Biochem Pharmacol 2014;88:426–49
   PubMed Web of Science ®Google Scholar
• Hampel H, Lista S. Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. J Nutr Health Aging 2013;17:54–63
   PubMed Web of Science ®Google Scholar
• Hampel H, Lista S. Alzheimer disease: from inherited to sporadic AD-crossing the biomarker bridge. Nat Rev Neurol 2012;8:598–600
   PubMed Web of Science ®Google Scholar
• Zetzsche T, Rujescu D, Hardy J, Hampel H. Advances and perspectives from genetic research: development of biological markers in Alzheimer’s disease. Expert Rev Mol Diagn 2010;10:667–90
   PubMed Web of Science ®Google Scholar
• Lista S, Garaci FG, Toschi N, Hampel H. Imaging epigenetics in Alzheimer’s disease. Curr Pharm Des 2013;19:6393–415
   PubMed Web of Science ®Google Scholar
• Lista S, O’Bryant SE, Blennow K, et al. Biomarkers in sporadic and familial Alzheimer’s Disease. J Alzheimers Dis 2015;47:291–317
   PubMed Web of Science ®Google Scholar
• Rosen C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer’s disease: current concepts. Mol Neurodegener 2013;8:20
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H, Fagan AM. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006221
   PubMed Web of Science ®Google Scholar
• Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010;6:131–44
   PubMed Web of Science ®Google Scholar
• Hampel H, Shen Y, Walsh DM, et al. Biological markers of amyloid beta-related mechanisms in Alzheimer’s disease. Exp Neurol 2010;223:334–46
   PubMed Web of Science ®Google Scholar
• Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer’s disease. Exp Gerontol 2010;45:30–40
   PubMed Web of Science ®Google Scholar
• O’Bryant SE, Lista S, Rissman RA, et al. Comparing biological markers of Alzheimer’s disease across blood fraction and platforms: comparing apples to oranges. Alzheimers Dement (Amst) 2016;3:27–34
   PubMedGoogle Scholar
• O’Bryant SE, Gupta V, Henriksen K, et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer’s disease research. Alzheimers Dement 2015;11:549–60
   PubMed Web of Science ®Google Scholar
• Henriksen K, O’Bryant SE, Hampel H, et al. The future of blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement 2014;10:115–31
   PubMed Web of Science ®Google Scholar
• Snyder HM, Carrillo MC, Grodstein F, et al. Developing novel blood-based biomarkers for Alzheimer’s disease. Alzheimers Dement 2014;10:109–14
   PubMed Web of Science ®Google Scholar
• Gupta VB, Sundaram R, Martins RN. Multiplex biomarkers in blood. Alzheimers Res Ther 2013;5:31
   PubMed Web of Science ®Google Scholar
• Teipel SJ, Grothe M, Lista S, Toschi N, Garaci FG, Hampel H. Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. Med Clin North Am 2013;97:399–424
   PubMed Web of Science ®Google Scholar
• Ewers M, Sperling RA, Klunk WE, Weiner MW, Hampel H. Neuroimaging markers for the prediction and early diagnosis of Alzheimer’s disease dementia. Trends Neurosci 2011;34:430–42
   PubMed Web of Science ®Google Scholar
• Lista S, Garaci FG, Ewers M, et al. CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer’s disease. Alzheimers Dement 2014;10:381–92
   PubMed Web of Science ®Google Scholar
• Poil SS, de Haan W, van der Flier WM, Mansvelder HD, Scheltens P, Linkenkaer-Hansen K. Integrative EEG biomarkers predict progression to Alzheimer’s disease at the MCI stage. Front Aging Neurosci 2013;5:58
   PubMed Web of Science ®Google Scholar
• Stam CJ. Use of magnetoencephalography (MEG) to study functional brain networks in neurodegenerative disorders. J Neurol Sci 2010;289:128–34
   PubMed Web of Science ®Google Scholar
• Jørgensen JT. Companion diagnostics: the key to personalized medicine. Foreword. Expert Rev Mol Diagn 2015;15:153–6
   PubMed Web of Science ®Google Scholar
• Lyman GH, Moses HL. Biomarker tests for molecularly targeted therapies: the key to unlocking precision medicine. N Engl J Med 2016;375:4–6
   PubMed Web of Science ®Google Scholar
• Doody RS, Raman R, Farlow M, et al. A phase 3 trial of semagacestat for treatment of Alzheimer’s disease. N Engl J Med 2013;369:341–50
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:322–33
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 2014;370:311–21
   PubMed Web of Science ®Google Scholar
• Noorbakhsh F, Overall CM, Power C. Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology. Trends Neurosci 2009;32:88–100
   PubMed Web of Science ®Google Scholar
• Castrillo JI, Oliver SG. Alzheimer’s as a systems-level disease involving the interplay of multiple cellular networks. Methods Mol Biol 2016;1303:3–48
   PubMedGoogle Scholar
• FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD): Food and Drug Administration (US), Bethesda (MD), National Institutes of Health (US), 2016
   Google Scholar
• Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet 2010;11:241–6
   PubMed Web of Science ®Google Scholar
• Zhang J, Chiodini R, Badr A, Zhang G. The impact of next-generation sequencing on genomics. J Genet Genomics 2011;38:95–109
   PubMed Web of Science ®Google Scholar
• Lambert JC, Ibrahim-Verbaas CA, Harold D, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet 2013;45:1452–8
   PubMed Web of Science ®Google Scholar
• Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature 2014;511:421–7
   PubMed Web of Science ®Google Scholar
• Daly AK. Pharmacogenetics and human genetic polymorphisms. Biochem J 2010;429:435–49
   PubMed Web of Science ®Google Scholar
• Guerreiro R, Wojtas A, Bras J, et al. TREM2 variants in Alzheimer’s disease. N Engl J Med 2013;368:117–27
   PubMed Web of Science ®Google Scholar
• Brinkmalm A, Portelius E, Öhrfelt A, et al. Explorative and targeted neuroproteomics in Alzheimer’s disease. Biochim Biophys Acta 2015;854:769–78
   Web of Science ®Google Scholar
• Veenstra TD. Neuroproteomic tools for battling Alzheimer’s disease. Proteomics 2016;16:2847–53
   PubMed Web of Science ®Google Scholar
• Proitsi P, Kim M, Whiley L, et al. Association of blood lipids with Alzheimer’s disease: a comprehensive lipidomics analysis. Alzheimers Dement 2016 Sept 28; doi: 10.1016/j.jalz.2016.08.003. Epub ahead of print
   PubMedGoogle Scholar
• Trushina E, Mielke MM. Recent advances in the application of metabolomics to Alzheimer’s Disease. Biochim Biophys Acta 2014;1842:1232–9
   PubMed Web of Science ®Google Scholar
• Czech C, Berndt P, Busch K, et al. Metabolite profiling of Alzheimer’s disease cerebrospinal fluid. PLoS One 2012;7:e31501
   PubMed Web of Science ®Google Scholar
• Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine. J Proteome Res 2004;3:179–96
   PubMed Web of Science ®Google Scholar
• Butcher EC, Berg EL, Kunkel EJ. Systems biology in drug discovery. Nat Biotechnol 2004;22:1253–9
   PubMed Web of Science ®Google Scholar
• O’Bryant SE, Mielke MM, Rissman RA, et al. Blood based biomarkers in Alzheimer’s disease: current state of the science and a novel collaborative paradigm for advancing discovery to clinic. Alzheimers Dement 2017;13:45–58
   PubMed Web of Science ®Google Scholar
• Hood L, Flores M. A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory. N Biotechnol 2012;29:613–24
   PubMed Web of Science ®Google Scholar
• Gligorijević V, Malod-Dognin N, Pržulj N. Integrative methods for analyzing big data in precision medicine. Proteomics 2016;16:741–58
   PubMed Web of Science ®Google Scholar
• Beyer MA, Laney D. The Importance of ‘Big Data’: A Definition. Stamford, CT: Gartner, 2012
   Google Scholar
• Margolis R, Derr L, Dunn M, et al. The National Institutes of Health’s Big Data to Knowledge (BD2K) initiative: capitalizing on biomedical big data. J Am Med Inform Assoc 2014;21:957–8
   PubMed Web of Science ®Google Scholar
• Geerts H, Dacks PA, Devanarayan V, et al. Big data to smart data in Alzheimer’s disease: the brain health modeling initiative to foster actionable knowledge. Alzheimers Dement 2016;12:1014–21
   PubMed Web of Science ®Google Scholar
• Haas M, Stephenson D, Romero K, Gordon MF, Zach N, Geerts H. Brain Health Modeling Initiative (BHMI). Big data to smart data in Alzheimer’s disease: real-world examples of advanced modeling and simulation. Alzheimers Dement 2016;12:1022–30
   PubMed Web of Science ®Google Scholar
• Saykin AJ, Shen L, Yao X, et al. Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities, and plans. Alzheimers Dement 2015;11:792–814
   PubMed Web of Science ®Google Scholar
• Choi IY, Kim TM, Kim MS, Mun SK, Chung YJ. Perspectives on clinical informatics: integrating large-scale clinical, genomic, and health information for clinical care. Genomics Inform 2013;11:186–90
   PubMedGoogle Scholar
• Bai JP, Abernethy DR. Systems pharmacology to predict drug toxicity: integration across levels of biological organization. Annu Rev Pharmacol Toxicol 2013;53:451–73
   PubMed Web of Science ®Google Scholar
• Maudsley S, Martin B, Janssens J, et al. Informatic deconvolution of biased GPCR signaling mechanisms from in vivo pharmacological experimentation. Methods 2016;92:51–63
   PubMed Web of Science ®Google Scholar
• Peck RW. The right dose for every patient: a key step for precision medicine. Nat Rev Drug Discov 2016;15:145–6
   PubMed Web of Science ®Google Scholar
• Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000;25:25–9
   PubMed Web of Science ®Google Scholar
• Malhotra A, Younesi E, Gündel M, Müller B, Heneka MT, Hofmann-Apitius M. ADO: A disease ontology representing the domain knowledge specific to Alzheimer’s disease. Alzheimers Dement 2014;10:238–46
   PubMed Web of Science ®Google Scholar
• Younesi E, Malhotra A, Gündel M, et al. PDON: Parkinson’s disease ontology for representation and modeling of the Parkinson’s disease knowledge domain. Theor Biol Med Model 2015;12:20
   PubMed Web of Science ®Google Scholar
• Sahoo SS, Lhatoo SD, Gupta DK, et al. Epilepsy and seizure ontology: towards an epilepsy informatics infrastructure for clinical research and patient care. J Am Med Inform Assoc 2014;21:82–9
   PubMed Web of Science ®Google Scholar
• Malhotra A, Gündel M, Rajput AM, et al. Knowledge retrieval from PubMed abstracts and electronic medical records with the multiple sclerosis ontology. PLoS One 2015;10:e0116718
   PubMed Web of Science ®Google Scholar
• Iyappan A, Gündel M, Shahid M, et al. Towards a pathway inventory of the human brain for modeling disease mechanisms underlying neurodegeneration. J Alzheimers Dis 2016;52:1343–60
   PubMed Web of Science ®Google Scholar
• Mizuno S, Iijima R, Ogishima S, et al. AlzPathway: a comprehensive map of signaling pathways of Alzheimer’s disease. BMC Syst Biol 2012;6:52
   PubMed Web of Science ®Google Scholar
• Kodamullil AT, Younesi E, Naz M, Bagewadi S, Hofmann-Apitius M. Computable cause-and-effect models of healthy and Alzheimer’s disease states and their mechanistic differential analysis. Alzheimers Dement 2015;11:1329–39
   PubMed Web of Science ®Google Scholar
• Martin F, Sewer A, Talikka M, Xiang Y, Hoeng J, Peitsch MC. Quantification of biological network perturbations for mechanistic insight and diagnostics using two-layer causal models. BMC Bioinformatics 2014;15:238
   PubMed Web of Science ®Google Scholar
• Benzinger TL, Blazey T, Jack CR, Jr., et al. Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease. Proc Natl Acad Sci USA 2013;110:E4502–9
   Google Scholar
• Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Pérez JM, Evans AC. Alzheimer’s Disease Neuroimaging InitiativeEarly role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun 2016;7:11934
   PubMed Web of Science ®Google Scholar
• Donohue MC, Jacqmin-Gadda H, Goff L, et al. Estimating long-term multivariate progression from short-term data. Alzheimers Dement 2014;10:S400–S10
   Google Scholar
• Samtani MN, Raghavan N, Shi Y, et al. Disease progression model in subjects with mild cognitive impairment from the Alzheimer’s disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br J Clin Pharmacol 2013;75:146–61
   PubMed Web of Science ®Google Scholar
• Delor I, Charoin JE, Gieschke R, Retout S, Jacqmin P. Modeling Alzheimer’s disease progression using disease onset time and disease trajectory concepts applied to CDR-SOB scores from ADNI. CPT Pharmacometrics Syst Pharmacol 2013;2:e78
   PubMedGoogle Scholar
• Gaser C, Franke K, Klöppel S, Koutsouleris N, Sauer H. Alzheimer’s Disease Neuroimaging InitiativeBrainAGE in mild cognitive impaired patients: predicting the conversion to Alzheimer’s disease. PLoS One 2013;8:e67346
   Google Scholar
• Lavielle M. Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools. Chapman & Hall/CRC Biostatistics Series. Boca Raton (FL): CRC Press, Taylor & Francis Group (US), 2015
   Google Scholar
• Durrleman S, Pennec X, Trouvé A, Gerig G, Ayache N. Spatiotemporal atlas estimation for developmental delay detection in longitudinal datasets. Med Image Comput Comput Assist Interv 2009;12:297–304
   PubMedGoogle Scholar
• Durrleman S, Pennec X, Trouvé A, Braga J, Gerig G, Ayache N. Toward a comprehensive framework for the spatiotemporal statistical analysis of longitudinal shape data. Int J Comput Vis 2013;103:22–59
   PubMed Web of Science ®Google Scholar
• Fonteijn HM, Modat M, Clarkson MJ, et al. An event-based model for disease progression and its application in familial Alzheimer’s disease and Huntington’s disease. Neuroimage 2012;60:1880–9
   PubMed Web of Science ®Google Scholar
• Jedynak BM, Lang A, Liu B, et al. A computational neurodegenerative disease progression score: method and results with the Alzheimer’s disease neuroimaging initiative cohort. Neuroimage 2012;63:1478–86
   PubMed Web of Science ®Google Scholar
• Schiratti JB, Allassonniere S, Colliot O, Durrleman S. Learning spatiotemporal trajectories from manifold-valued longitudinal data. Presented at the Advances in Neural Information Processing Systems 28 (NIPS 2015); 2015. 2404–12
   Google Scholar
• Schiratti JB, Allassonniere S, Routier A, Colliot O, Durrleman S, A mixed-effects model with time reparametrization for longitudinal univariate manifold-valued data. Presented at the 24th International Conference, IPMI 2015: Information Processing in Medical Imaging, Sabhal Mòr Ostaig, Isle of Skye, UK, Jun 2015. 564–75
   Google Scholar
• Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med 2013;368:1326–34
   PubMed Web of Science ®Google Scholar
• Dubois B, Hampel H, Feldman HH, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 2016;12:292–323
   PubMed Web of Science ®Google Scholar